RGS Stock Overview
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Regeneus Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.02 |
| 52 Week Low | AU$0.003 |
| Beta | -0.26 |
| 1 Month Change | 116.67% |
| 3 Month Change | n/a |
| 1 Year Change | 8.33% |
| 3 Year Change | -90.00% |
| 5 Year Change | -87.62% |
| Change since IPO | -95.19% |
Recent News & Updates
Shareholder Returns
| RGS | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 160.0% | 1.8% | 1.3% |
| 1Y | 8.3% | 3.6% | 9.5% |
Return vs Industry: RGS underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: RGS underperformed the Australian Market which returned 9.6% over the past year.
Price Volatility
| RGS volatility | |
|---|---|
| RGS Average Weekly Movement | 32.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: RGS's share price has been volatile over the past 3 months.
Volatility Over Time: RGS's weekly volatility has decreased from 41% to 32% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Karolis Rosickas | regeneus.com.au |
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company’s platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing.
Regeneus Ltd Fundamentals Summary
| RGS fundamental statistics | |
|---|---|
| Market cap | AU$1.53m |
| Earnings (TTM) | -AU$366.01k |
| Revenue (TTM) | AU$988.43k |
4.0x
P/S Ratio-10.9x
P/E RatioIs RGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGS income statement (TTM) | |
|---|---|
| Revenue | AU$988.43k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$988.43k |
| Other Expenses | AU$1.35m |
| Earnings | -AU$366.01k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0012 |
| Gross Margin | 100.00% |
| Net Profit Margin | -37.03% |
| Debt/Equity Ratio | 0% |
How did RGS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/05 10:26 |
| End of Day Share Price | 2024/04/05 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Regeneus Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |